D5D-IN-326 (Compound-326) is an orally available, potent and selective inhibitor of delta-5 desaturase (D5D) that reduces insulin resistance and body weight in a high-fat diet-induced obese mice. It appears that D5D-IN-326 significantly inhibits the progression of atherosclerosis in the aorta of western-diet fed ApoE knockout (KO) mice. It is called Compound-326 in recent J Pharmacol Exp Ther. 2019 Nov;371(2):290-298. (PMID: 31488602) paper.
orally available, potent and selective inhibitor of delta-5 desaturase (D5D)
The Journal of pharmacology and experimental therapeutics, 371(2), 290-298 (2019-09-07)
Delta-5 desaturase (D5D), encoded by fatty acid desaturase 1 (Fads1), is the rate-limiting enzyme for the conversion from dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) in the ω-6 polyunsaturated fatty acid pathway. Several AA-derived eicosanoids (e.g., prostaglandins, thromboxanes, and leukotrienes)
Obesity is now recognized as a state of chronic low-grade inflammation and is called as metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D inhibition increases DGLA (precursor to anti-inflammatory
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.